Virus Clinical Trial - Genetic Determinants of the Antiviral Immune

Status Not yet recruiting

Clinical Trial Summary

Oceania's populations, including Melanesians, are paying a heavy price for dengue fever, which has been circulating actively in the region since the Second World War. In New Caledonia (NC), the incidence of dengue fever is higher among municipalities predominantly populated by Melanesians, suggesting that Melanesians may have an increased susceptibility to symptomatic dengue fever. Differences in antiviral immune responses between populations of different geographical origins are partly the result of population-specific immune regulatory variants. In turn, viruses have imposed considerable selective pressure on human populations. Although crucial to understanding their susceptibility to viral infections, the genetic determinants of the antiviral immune response of Oceanians remain to be characterized. In this context, we hypothesize that the genetic origin of Oceanians, and Melanesians in particular, has shaped their antiviral immune response and contributes to their greater susceptibility to certain viral infections. We aim to characterize the immune response to pathogens affecting the New Caledonian population, and in particular to dengue virus, of Melanesian and European populations, and to identify its genetic determinants. We will also explore whether saliva can be used as a non-invasive sample to study the seroprevalence of dengue in Oceanian populations.

Clinical Trial Description

Cross-sectional observational study with prospective sample and data collection Individuals will be identified from among eligible participants in the STEP-BSA21 and COVCAL studies. Information and consent Questionnaire, saliva collection on Oragene tube, buccal swabbing and 20 mL blood collection on CPT tube DNA extraction and low-coverage sequencing of participants' complete genomes And Isolation and in vitro stimulation of peripheral blood mononuclear cells (PBMCs) with dengue virus - single-cell RNA sequencing (scRNAseq) - multiplex quantification of cytokines and chemokines - bioinformatics analysis to identify genetic markers associated with a differential transcriptomic and secretory response to dengue virus stimulation. ;

Study Design

Related Conditions & MeSH terms

Virus

Clinical Trial Details

NCT number	NCT06432855
Study type	Interventional
Source	Institut Pasteur
Contact	Catherine Inizan, PhD
Phone	+687 27 26 66
Email	cinizan@pasteur.nc
Status	Not yet recruiting
Phase	N/A
Start date	June 15, 2024
Completion date	December 15, 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03911388` - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	Phase 1
Recruiting	`NCT06059027` - Microbes and Respiratory Illnesses
Completed	`NCT03463694` - Edinburgh and Lothian Virus Intervention Study in Kids	N/A
Recruiting	`NCT04393415` - Using PRP and Cord Blood in Treatment of Covid -19	N/A
Not yet recruiting	`NCT05387226` - Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma	Phase 1
Active, not recruiting	`NCT05064462` - TTV Viral Load in Heart Transplant Recipients
Recruiting	`NCT04336020` - The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study
Recruiting	`NCT05727709` - Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients
Recruiting	`NCT04382131` - Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)	N/A
Completed	`NCT02743663` - The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children
Not yet recruiting	`NCT06396624` - Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis	N/A
Not yet recruiting	`NCT05868551` - Onchocerciasis-Associated Epilepsy, an Explorative Case-control Study
Completed	`NCT01136395` - Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation	Phase 2
Completed	`NCT01159561` - Western Equine Encephalitis Vaccine, Inactivated	Phase 1
Completed	`NCT04636294` - Borderline COVID-19 PCR Test Result
Recruiting	`NCT04449978` - TARGet Kids! COVID-19 Study of Children and Families
Recruiting	`NCT06135844` - Hand Sanitizer Use for Herpes Simplex Virus-1	Early Phase 1
Recruiting	`NCT04348864` - COVID-19 Diagnostic Self-testing Using Virtual Point-of-care	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Genetic Determinants of the Antiviral Immune Response in Oceanian Populations — GEDIPOP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms